Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation

NCT07211958 is registered in ClinicalTrials.gov with Syndax Pharmaceuticals as lead sponsor.

NCT NCT07211958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07211958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation
Lead sponsor
Syndax Pharmaceuticals
Phase
Phase 3
Overall status
Recruiting
Start date
November 25, 2025
Completion date
January 31, 2031
Enrollment
468 (estimated)
Sites
149

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemias